🇺🇸 FDA
Pipeline program

ATRN-119

859861

Phase 2 small_molecule active

Quick answer

ATRN-119 for HPV Positive Oropharyngeal Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aprea Therapeutics
Indication
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials